18F-FDG-PET/CT	18F-fluorodeoxyglucose positron emission tomography/computed tomography
5-FU	5-fluorouracil
ACQ	Aggregation-induced quenching
AIE	Aggregation-induced emission
ALT	Alanine transaminase
AOM	Azoxymethane
APCs	Antigen-presenting cells
AST	Aspartate transaminase
BSA	Bovine serum albumin
CAC	Colitis-associated cancer
CFUs	Colony-forming units
CMF	Cyclophosphamide (CTX) + methotrexate (MTX) + 5-fluorouracil (5-FU)
CP	Capsular polysaccharide
CRC	Colorectal cancer
CREA	Creatinine
CTX	Cyclophosphamide
DBCO	Dibenzocyclooctyne
DMSNs	Dendritic mesoporous silica nanoparticles
DOX	Doxorubicin
DSS	Dextran sodium sulfate
EMA	European Medicines Agency
EMT	Epithelial–mesenchymal transition
EPI	Epirubicin
EPR	Enhanced permeability and retention
FDA	Food and Drug Administration
FDU	Fluorouridine
FISH	Fluorescence in situ hybridization
FOLFIRINOX	Folinic acid (leucovorin) + fluorouracil (5-FU) + irinotecan + oxaliplatin
FOLFOX	Folinic acid (leucovorin) + fluorouracil (5-FU) + oxaliplatin
GSH	Glutathione
HA	Hyaluronic acid
H&E	Hematoxylin–eosin staining
IBD	Inflammatory bowel disease
IHC	Immunohistochemistry
IRT	Irinotecan
i.g.	Intragastric
i.t.	Intratumoral
i.v.	Intravenous
LA	Lauric acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
Luc	Luciferase
MDSCs	Myeloid-derived suppressor cells
MET	Metronidazole
MTI	Metronidazole
MON	Metal–organic network
MSN	Mesoporous silica nanoparticles
MTX	Methotrexate
NIR	Near-infrared
NK	Natural killer cells
NPs	Nanoparticles
OEI	Oligomethyleneimine
OSF	Open Science Framework
OXA	Oxaliplatin
PBA	Phenylboric acid
PDT	Photodynamic therapy
Ppa	Pyropheophorbide-a
PTT	Photothermal therapy
PVP	Polyvinyl pyrrolidone
ROS	Reactive oxygen species
RT–qPCR	Reverse transcription quantitative polymerase chain reaction
SDT	Sonodynamic therapy
Sg	Streptococcus gallolyticus
s.c.	Subcutaneous
TAMs	Tumor-associated macrophages
TME	Tumor microenvironment
Treg	Regulatory T cells
ZIF	Zinc-imidazolate frameworks